Business Wire

Ian Read named Chairman of the Board of Areteia Therapeutics

Share

Areteia Therapeutics, Inc. (“Areteia”) today announced that its Board of Directors has appointed Ian Read as Chairman of the Board. Mr. Read’s appointment as Areteia’s first Chairman follows the launch of the Company by Knopp Biosciences and Population Health Partners and the successful completion of the Company’s $350 million Series A financing led by Bain Capital Life Sciences, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.

“I am excited that Ian has been appointed as Chairman,” said Jorge Bartolome, Chief Executive Officer of Areteia. “He is an incredibly esteemed executive whose depth of experience, proven leadership and expert judgment will be invaluable to me and the Board of Directors as we focus on delivering on the Company’s strategy and advancing the Phase III program for dexpramipexole, the first potential oral drug for eosinophilic asthma.”

Commenting on his appointment, Mr. Read said, “I am honored to be chosen to serve as Chairman of Areteia and look forward to working with Jorge and the team. This is a compelling opportunity to address a high unmet need for severe asthmatics by bringing a new oral medicine to market to potentially treat eosinophilic asthma earlier in the treatment paradigm and offer patients and health systems an alternative to injectable biologics.”

Mr. Read brings to his role a distinguished 42-year track record as one of the foremost leaders, dealmakers, and value creators in the global biopharmaceutical industry. He was Chairman and Chief Executive Officer of Pfizer, Inc. from December 2010 until January 2019, and Executive Chairman until December 2019. During that tenure, he oversaw over 30 new drug approvals, $88 billion in acquisition and divestiture deals, and a total shareholder return of 250%—representing over $242 billion in value creation. Mr. Read oversaw a period of industry-shaping innovation regarding the structure of Pfizer and its portfolio, including novel spin-outs and acquisitions alongside dozens of major licensing agreements. Mr. Read currently serves as a partner of Population Health Partners.

About Areteia Therapeutics

Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development, including Phase III clinical trials of dexpramipexole, in partnership with Population Health Partners’ development unit, Validae Health.

About Dexpramipexole

Dexpramipexole is an oral small molecule in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.

About Eosinophilic Asthma

Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tamsin Berry
Tamsin.Berry@areteiatx.com

Mark Kreston
Mark.Kreston@areteiatx.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International Demonstrates Clear Progress Toward Its Purpose as It Releases 2023 Integrated Report28.3.2024 12:38:00 CET | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today releases its fifth annual Integrated Report, which outlines the company’s ongoing work to advance toward its 2025 Roadmap goals, with the primary focus on addressing the health impacts of the company’s products. The 2023 Integrated Report highlights PMI’s continued expansion of smoke-free alternatives in markets worldwide, as well as social and environmental programs deployed with and in parallel to these products—including the deployment of responsible marketing and sales practices and efforts to reduce post-consumer waste. Further, PMI reports its progress toward fostering an empowered and inclusive workplace, improving the quality of life of people in its supply chain, decarbonizing its operations and value chain, and preserving nature and biodiversity. “2023 was a year marked by unity, determination, and a continued commitment to our vision of a smoke-free future,” said Jacek Olczak, Chief Executive Officer of PMI. “As we enco

Wolters Kluwer named Market Leader in BARC Score Financial Performance Management 202428.3.2024 12:09:00 CET | Press release

Wolters Kluwer, a global leader in information, software, and services for professionals, today announces that its CCH® Tagetik expert solution has retained its leadership position for the seventh consecutive year in both the Global and DACH region issues of the prestigious BARC Score Financial Performance Management (FPM) Report. Developed by BARC, one of Europe’s leading analyst firms for business software, the reports highlight CCH Tagetik’s strength as a unified platform for financial corporate management (financial consolidation and close; budgeting, planning, and forecasting; ESG and regulatory reporting; corporate tax) that can be used by individual subsidiaries or at group level. Ralf Gärtner, Senior Vice President and General Manager of Corporate Performance & ESG, Wolters Kluwer, said: “The BARC Score FPM Reports have ranked CCH Tagetik as a market leader year after year, recognizing our consistent commitment to product excellence and innovation. We are focused on empowering

Cirium’s Airfare Data Shows Increases in Economy Airfares in 2023 in North America and Europe With a Decrease in Transatlantic Business Class Fares28.3.2024 11:37:00 CET | Press release

Cirium, the leading aviation analytics company, analysed airfare trends for 2023, using Cirium FM Traffic. Economy airfare has generally increased since 2023 in North America and Europe, but lower than the U.S. inflation rate. “While airfare has risen in nominal terms in U.S. and Europe, consumers will appreciate that the increases are less than other consumables,” said Jeremy Bowen, CEO of Cirium. “Cirium’s data teams will continue to monitor the impact on fares of increased capacity in the market, despite challenges related to the availability of aircraft, be it due to groundings, engine issues, or supply chain constraints.” Cirium analysed airfare for the U.S. domestic market (including 13 U.S. airlines), intra-European travel, and the Transatlantic market. The data is non-directionally averaged, in U.S. dollars, not including taxes and fees. Unless otherwise noted, the fares indicated are for economy class. U.S. Domestic Airfare The average U.S. domestic airfare by the 13 airlines

Ministry of Education and Science of Ukraine and Palantir Partner to Create Safe Conditions for In-Person Education in Schools28.3.2024 10:00:00 CET | Press release

The Ministry of Education and Science, along with Palantir (NYSE:PLTR), a leading provider of AI systems, have signed an agreement. The main goal is to facilitate qualitative transformations in the field of education and ensure the maximum number of children have access to safe in-person learning. The agreement, initially for 12 months, will support the Government’s official School Offline initiative which aims to provide 300,000 more Ukrainian pupils with safe access to a school. New software tooling will enable: Funding allocated for school bomb shelters to be targeted where it will deliver the greatest benefit for children and young people of a school age. Every school to receive a risk rating according to a methodology recently adopted in law as a Cabinet of Ministers decree, in order to help identify targeted measures that will improve the safety of a school. The rating will take into account factors such as historic shelling in the area, presence of a bomb shelter, safety of acce

Guidewire Jasper Release Boosts Commercial Lines Agility for P&C Insurers and Strengthens Functionality Across Entire Product Portfolio28.3.2024 08:05:00 CET | Press release

Guidewire (NYSE: GWRE) announces Jasper, its latest release, which boosts commercial lines agility for P&C insurers with support for layered coinsurance, schedule import, and a new U.S. Bureau Content Solution.* Additionally, expanded HazardHub data for Canada gives insurers deeper property risk insights for underwriting precision. Jasper release will be generally available on April 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328607054/en/ “Commercial lines insurers face both risk and opportunity. On the one hand, there are economic fluctuations, including inflation, geopolitical complexities, capital limitations, and environmental challenges. On the other hand, the protection gap creates growth opportunities for insurers that innovate to stay ahead of the evolving risk landscape,” said Eugene Lee, senior vice president and general manager, InsuranceSuite, Guidewire. For P&C insurers seeking to improve commerc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye